Document Detail


Adherence with Migraine Prophylaxis in Clinical Practice.
MedLine Citation:
PMID:  22300068     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective:  To characterize adherence with antidepressants, antiepileptic drugs, and beta blockers as prophylaxis against migraine in typical clinical practice. Methods:  Using a large US health insurance claims database (calendar years 2003 to 2005), we identified all patients with migraine who began prophylaxis with selected antidepressants, antiepileptic drugs, or beta blockers ("study agents"). Patients not continuously enrolled for 6 months prior to start of prophylaxis ("pretreatment") and for 6 months subsequently ("follow-up") were excluded. Treatment cohorts were constituted based on the type of prophylaxis received. Adherence with migraine prophylaxis was examined by type of agent received using medication possession ratios (MPRs), defined as total days with medication divided by total follow-up days. MPR < 0.80 was considered indicative of nonadherence. Results:  A total of 4,634 patients met all entry criteria and received antidepressants (n = 1,803), antiepileptics (n = 1,896), or beta blockers (n = 935) on their index date. Over the next 6 months, the mean (SD) number of prescriptions for study agents was 2.7 (1.9) for antidepressants, 2.9 (2.0) for antiepileptics, and 2.8 (2.0) for beta blockers, totaling 91.0 (71.4), 98.7 (75.6), and 96.7 (73.0) therapy-days, respectively. Mean MPR at 6 months was 0.48 for antidepressants, 0.51 for antiepileptics, and 0.51 for beta blockers. By the end of the follow-up, 73.4%, 70.2%, and 67.6% of patients who initiated migraine prophylaxis with antidepressants, antiepileptics, and beta blockers, respectively, were designated nonadherent (ie, MPR < 0.80). Conclusion:  Our findings suggest that many patients who begin migraine prophylaxis with antidepressants, antiepileptics, or beta blockers are no longer taking these medications at 6 months.
Authors:
Ariel Berger; Lisa M Bloudek; Sepideh F Varon; Gerry Oster
Related Documents :
2025058 - Intraoperative identification of cardiac patients at risk to develop postoperative atri...
10535368 - A perspective on postoperative atrial fibrillation.
19950088 - Efficacy and tolerability of oral propafenone versus quinidine in the treatment of rece...
14565648 - Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
22855398 - Factors associated with fluoroscopy exposure during pediatric catheter ablation utilizi...
22214928 - Use of autogenous bone graft compared with rhbmp in high-risk patients: a comparison of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-2
Journal Detail:
Title:  Pain practice : the official journal of World Institute of Pain     Volume:  -     ISSN:  1533-2500     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101130835     Medline TA:  Pain Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Allergan, Inc. Pain Practice © 2012 World Institute of Pain.
Affiliation:
Policy Analysis, Inc. (PAI), Brookline, Massachusetts Allergan Inc., Irvine, California, U.S.A.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Suppressive effects of liquid crystal compounds on the growth of U937 human leukemic monocyte lympho...
Next Document:  A preliminary study to find a possible association between occlusal wear and maximum bite force in h...